Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Medexus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Medexus Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 46.9% bzw. 5.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 39.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 30.3% betragen.

Wichtige Informationen

46.9%

Wachstumsrate der Gewinne

39.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	72.9%
Wachstumsrate der Einnahmen	5.4%
Zukünftige Eigenkapitalrendite	30.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06

Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 21

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Aug 04

Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?

May 04

The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares

Feb 26

Did Business Growth Power Medexus Pharmaceuticals' (CVE:MDP) Share Price Gain of 174%?

Feb 24

Gewinn- und Umsatzwachstumsprognosen

TSX:MDP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	127	9	11	30	3
3/31/2026	123	4	-7	26	3
3/31/2025	114	1	-7	21	6
3/31/2024	113	-1	22	22	6
12/31/2023	116	6	21	21	N/A
9/30/2023	119	5	13	13	N/A
6/30/2023	117	3	6	7	N/A
3/31/2023	108	1	-2	-1	N/A
12/31/2022	100	-11	-3	-2	N/A
9/30/2022	92	-11	-3	-1	N/A
6/30/2022	82	2	0	2	N/A
3/31/2022	77	-3	-9	-1	N/A
12/31/2021	74	-8	-17	-1	N/A
9/30/2021	77	-20	-18	-1	N/A
6/30/2021	77	-31	-21	-5	N/A
3/31/2021	80	-28	-6	5	N/A
12/31/2020	79	-19	-1	0	N/A
9/30/2020	69	-9	1	1	N/A
6/30/2020	64	-7	1	1	N/A
3/31/2020	56	-5	-3	-2	N/A
12/31/2019	47	-4	-1	0	N/A
9/30/2019	45	-3	-1	0	N/A
6/30/2019	36	-6	-2	-1	N/A
3/31/2019	25	-5	-1	-1	N/A
12/31/2018	17	-5	-3	-2	N/A
9/30/2018	9	-5	-1	-1	N/A
6/30/2018	8	-2	-2	-2	N/A
3/31/2018	8	-3	-4	-3	N/A
12/31/2017	8	-3	-4	-3	N/A
9/30/2017	7	-3	N/A	-4	N/A
6/30/2017	6	-3	N/A	-4	N/A
3/31/2017	5	-1	N/A	-1	N/A
12/31/2016	4	1	N/A	1	N/A
9/30/2016	3	1	N/A	1	N/A
6/30/2016	3	1	N/A	1	N/A
3/31/2016	3	-2	N/A	-1	N/A
12/31/2015	3	-4	N/A	-3	N/A
9/30/2015	2	-4	N/A	-3	N/A
6/30/2015	2	-5	N/A	-3	N/A
3/31/2015	2	-4	N/A	-4	N/A
12/31/2014	3	-4	N/A	-3	N/A
9/30/2014	3	-4	N/A	-3	N/A
6/30/2014	4	-3	N/A	-3	N/A
3/31/2014	3	-3	N/A	-1	N/A
12/31/2013	4	-2	N/A	-1	N/A
9/30/2013	3	-1	N/A	-1	N/A
6/30/2013	3	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDPDas prognostizierte Gewinnwachstum (46.9% pro Jahr) liegt über der Sparquote (2.1%).

Ertrag vs. Markt: MDPDie Erträge des Unternehmens (46.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (13.7% pro Jahr).

Hohe Wachstumserträge: MDPEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: MDPDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Canadian (6.9% pro Jahr).

Hohe Wachstumseinnahmen: MDPDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MDPDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (30.3%)

Medexus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates have been downgraded.

Price target decreased by 15% to CA$3.61

Consensus EPS estimates fall by 46%

Consensus EPS estimates increase by 414%

Consensus EPS estimates increase by 1,654%, revenue downgraded

Price target increased by 8.4% to CA$3.53

Recent updates

Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDA

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Investor sentiment improves as stock rises 15%

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Consensus EPS estimates have been downgraded.

New minor risk - Share price stability

Price target decreased by 15% to CA$3.61

Investor sentiment improves as stock rises 15%

Medexus Pharmaceuticals Inc. to Report Q3, 2024 Results on Feb 07, 2024

Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 22%

Consensus EPS estimates fall by 46%

Medexus Pharmaceuticals Inc. to Report Q2, 2024 Results on Nov 08, 2023

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Investor sentiment deteriorates as stock falls 17%

Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million.

New minor risk - Shareholder dilution

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY

Consensus EPS estimates increase by 414%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 42%

Medexus Pharmaceuticals Inc. to Report Q1, 2024 Results on Aug 09, 2023

New minor risk - Shareholder dilution

Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023

Independent Director recently bought CA$131k worth of stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 1,654%, revenue downgraded

Price target increased by 8.4% to CA$3.53

New major risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Medexus Pharmaceuticals Inc. to Report Q4, 2023 Results on Jun 21, 2023

Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023

CEO & Director exercised options to buy CA$76k worth of stock.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medexus Pharmaceuticals Inc. Announces Board Appointments

Medexus Pharmaceuticals Inc. to Report Q3, 2023 Results on Feb 08, 2023

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Consensus estimates of losses per share improve by 11%

Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023

Forecast breakeven date moved forward to 2024

Price target increased to CA$5.88

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medexus Pharmaceuticals Inc. to Report Q2, 2023 Results on Nov 08, 2022

Investor sentiment improved over the past week

Medexus Pharmaceuticals Inc. Provides Revenue Guidance for the Second Fiscal Quarter Ended September 30, 2022

Investor sentiment improved over the past week

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals Provides Update on Treosulfan NDA Resubmission and Provides Business Update

Investor sentiment deteriorated over the past week

Consensus estimates of losses per share improve by 14%

Investor sentiment improved over the past week

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medexus Pharmaceuticals Inc. to Report Q1, 2023 Results on Aug 08, 2022

Insufficient new directors

Forecast breakeven date pushed back to 2025

Medexus Pharmaceuticals Inc. and Medac Resubmits New Drug Application for Treosulfan with the U.S. Food and Drug Administration

Consensus forecasts updated

Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 15, 2022

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medexus Pharmaceuticals Inc. to Report Q4, 2022 Results on Jun 22, 2022

Medexus Pharmaceuticals Announces American Journal of Hematology Has Accepted for Publication the Final Study Results

Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Consensus estimates of losses per share improve by 18%